CT-based clinical-radiomics model to predict progression and drive clinical applicability in locally advanced head and neck cancer - Takeaways - MDSpire

CT-based clinical-radiomics model to predict progression and drive clinical applicability in locally advanced head and neck cancer

  • By

  • Gema Bruixola

  • Delfina Dualde-Beltrán

  • Ana Jimenez-Pastor

  • Anna Nogué

  • Fuensanta Bellvís

  • Almudena Fuster-Matanzo

  • Clara Alfaro-Cervelló

  • Nuria Grimalt

  • Nader Salhab-Ibáñez

  • Vicente Escorihuela

  • María Eugenia Iglesias

  • María Maroñas

  • Ángel Alberich-Bayarri

  • Andrés Cervantes

  • Noelia Tarazona

  • December 20, 2024

  • 0 min

Share

  • 1

    Head and neck squamous cell carcinoma (HNSCC) is the seventh most prevalent cancer globally, with significant risk factors including tobacco and HPV infection.

  • 2

    Over 60% of HNSCC cases are locally advanced, and standard treatment involves high-dose cisplatin with concurrent radiotherapy.

  • 3

    Current prognostic models for HNSCC, including the TNM8 staging system, are suboptimal and lack external validation for clinical use.

  • 4

    A CT-based radiomics model integrating clinical and biological data aims to improve progression-free survival predictions in locally advanced HNSCC.

  • 5

    The Shapley additive explanations (SHAP) method enhances model interpretability by assigning values to features based on their influence on predictions.

Original Source(s)

Related Content